J&J's block­buster hope­ful erdafi­tinib gets 'break­through' moniker

Janssen has snagged the FDA’s break­through sta­tus on its sol­id tu­mor drug can­di­date erdafi­tinib, putting J&J one step clos­er to its lofty goal of bring­ing nu­mer­ous new block­buster drugs to mar­ket.

The drug, an FGFR in­hibitor, got the des­ig­na­tion for its po­ten­tial to treat pa­tients with metasta­t­ic urothe­lial can­cer. Urothe­lial can­cer is the sixth most com­mon type of can­cer in the US, most fre­quent­ly show­ing up in the blad­der.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.